Search Results

Enrollment completed in Actinogen’s XanaCIDD phase 2a cognition & depression trial

Actinogen Medical Limited (ASX: ACW) announces the full enrollment of 167 participants in the Company’s XanaCIDD phase 2a clinical trial in patients with cognitive impairment in major depressive disorder (MDD).

April 22, 2024

·

7 min read

Drug Development

First patient treated in Actinogen’s XanaMIA phase 2b Alzheimer’s disease trial

Actinogen Medical Limited announces that the first patient has been randomized and treated in the XanaMIA phase 2b clinical trial in patients with biomarker-positive mild to moderate Alzheimer’s disease (AD).

April 15, 2024

·

8 min read

Press Releases

Actinogen announces further positive results on depression in the XanCIDD phase 2a trial

August 26, 2024

·

9 min read

Press Releases

Actinogen announces achievement of clinically and statistically significant superiority of Xanamem® over placebo on depression in XanaCIDD phase 2a trial

August 12, 2024

·

10 min read

Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer’s Disease (CTAD) Conference, Boston

Actinogen Medical Limited (ASX: ACW) CEO Dr Steven Gourlay will conduct a series of meetings at the BIO Investor Forum, San Francisco on October 17-18, 2023.

October 13, 2023

·

8 min read

Drug Development

Actinogen optimizes XanaMIA Phase 2b Alzheimer’s disease trial design and provides general business update

Actinogen Medical Limited (ASX: ACW) is pleased to announce optimization of the XanaMIA Phase 2b trial in patients with mild-to-moderate Alzheimer’s disease to reduce the cost and time to initial results.

September 26, 2023

·

9 min read

Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer’s Disease Phase 2 trials at the BIO International Convention

Actinogen Medical Limited (ASX: ACW) CEO Dr Steven Gourlay and CMO Dr Dana Hilt will present at the BIO International Convention, to be held at the Boston Convention & Exhibition Center from June 5-8, 2023.

May 31, 2023

·

7 min read

Actinogen presents positive Phase 2a Xanamem data in at ADPD™ Alzheimer’s and Parkinson’s diseases conference

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that its Chief Medical Officer, Dr Dana Hilt will make an oral presentation to the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (ADPD™ 2023) later today in Gothenburg, Sweden.

March 30, 2023

·

6 min read

Drug Development

Positive Xanamem® biomarker trial published in the Journal of Alzheimer’s Disease demonstrating potential Xanamem efficacy in patients with elevated blood pTau

Actinogen Medical Limited announces the peer-reviewed publication of its phase 2a biomarker trial entitled “Plasma pTau181 Predicts Clinical Progression In A Phase 2 Randomized Controlled Trial of the 11β-HSD1 Inhibitor Xanamem for Mild Alzheimer’s Disease” in the 100th edition of the Journal of Alzheimer’s Disease.

June 26, 2024

·

9 min read

Drug Development

Actinogen Medical Limited (ACW) announces large Xanamem® therapeutic effect in early-stage Alzheimer’s Disease (AD) patients

Actinogen Medical Limited (ASX: ACW) today announces positive Phase 2a clinical data from its Alzheimer’s Disease (AD) biomarker study.

October 10, 2022

·

10 min read